Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study

Clinical Neuropharmacology

Volumn 36, Issue 1, 2013, Pages 14-23

  Landen, Jaren W ^a   Zhao, Qinying ^a   Cohen, Sharon ^b   Borrie, Michael ^c   Woodward, Michael ^d   Billing, Clare B ^a   Bales, Kelly ^a   Alvey, Christine ^a   McCush, Fred ^a   Yang, Jerry ^e   Kupiec, James W ^a   Bednar, Martin M ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Toronto Memory Program   (Canada)

^c PARKWOOD HOSPITAL   (Canada)

^d AUSTIN HEALTH   (Australia)

^e PFIZER INC   (United States)

Author keywords

Amyloid A (AA); dementia; immunotherapy; monoclonal antibody; pharmacokinetics

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; PLACEBO; PONEZUMAB;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRAIN DAMAGE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MENINGOENCEPHALITIS; NEUROPHARMACOLOGY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84872960603     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31827db49b     Document Type: Article

References (23)

1. Wippold FJ 2nd, Cairns N, Vo K, et al. Neuropathology for the neuroradiologist: plaques and tangles. AJNR Am J Neuroradiol 2008;29:18-22.
2. Bednar M. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease. Drugs 2009;12:566-575.
3. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-1562.
4. Gilman S. Clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy, in patients with mild-to-moderate Alzheimer's disease. Presented at the International Conference on Alzheimer's Disease, Chicago, Illinois, July 26-31, 2008, Abstract O3-04-05.
5. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-2070.
6. Salloway S, Sperling R, Honig L, et al. Long-term follow-up of AD patients treated with bapineuzumab in phase 2. Presented at the Alzheimer's Association International Conference, Paris, France. Jul 16-21, 2011, Abstract O4-08-07.
7. Barakos J, Carlson C, Estergard W, et al. Vasogenic edema in the setting of A-amyloid lowering therapy, adverse event: what is it and how is it detected? Alzheimers Dementia 2011;7(Suppl):e75.
8. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4):367-385.
9. Armour KL, van de Winkel JG, Williamson LM, et al. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003;40:585-593.
10. LaPorte S, Bollini SS, Lanz TA, et al. Structural basis of C-terminal A-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 2012. In press.
11. Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26(20):5340-5346.
12. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against AA in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1;1-24.
13. Du P, Wood KM, Rosner MH, et al. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J Pharmacol Exp Ther 2007;320(3):1144- 1152.
14. Fredrickson J, Maruff P, Woodward M, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology 2010;34:65-75.
15. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
16. Freeman GB, Lin JC, Pons J, et al. 39-Week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 2012;28:531-541.
17. Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010;74(24):1954-1960.
18. Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 2012;38:1-17.
19. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33(2):67-73.
20. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24(2):198-203.
21. Pons J. Designing safer antibodies targeting AA for the treatment of Alzheimer's disease. Presented at the Antibody Discovery and Development Forum, Amsterdam, April 14-15, 2008.
22. Landen J, Cohen S, Billing CB Jr, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of multiple doses of ponezumab in subjects with mild-to-moderate Alzheimer's disease. Presented at the Alzheimer's Association International Conference, Vancouver, BC, Canada, July 14-19, 2012 (proposal number 31178).
23. Landen J, Andreasen N, Cronenberger C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of monthly and quarterly doses of ponezumab (PF-04360365) in subjects with mild-to-moderate Alzheimer's disease. Presented at the Alzheimer's Association International Conference, Vancouver, BC, Canada, July 14-19, 2012 (proposal number 31238).